Date : 12-12-2023

To,
Mr. Muhammad Karman Zaman Rana,
AGP Pharma Pvt. Ltd.
B-23-C, S.I.T.E., Karachi-75700, Pakistan

Subject: Investigation of Black Spots on Calfina Plus Tablet B#167 & Batch # 954

Respected Sir,

Reference to your email dated 20th November, 2023 regarding complaint of Calfina Plus tablets B#167 &
Batch # 954.

Wenovo Pharmaceuticals has been Manufacturing Calfina Plus tablets for more than 7 years without any
quality complaint. This is the first time we have received such like complain and we are highly concerned
about this issue.

We have investigated the matter and found the same spotting issue in some of our retained samples. We
have extended our investigation to other batches (Batch No 956, 034, 037, 152, 174, 321) of same
product and found no such spotting issue in all other batches.

During investigation of subject batches, it was found that these spot are superficial whereas all other
quality parameters against specifications were found to be within normal limits. However we are still
investigating the cause of these superficial black spots.

We will also like to discuss and seek guidance from AGP Quality Control Team to further investigate the
issue and find solution for prevention of any such complaint in future. Your guidance and cooperation in
this regards will be highly appreciated.

It is further requested to kindly recall the subject batches at the earliest and Wenovo Pharmaceuticals
will replace the recalled stock.

Thanks for the kind understanding and cooperation.

Manager Quality Control

Wenovo Pharmaceuticals